https://www.cigna.com/knowledge-center/hw/medications/epcoritamab-bysp-injection-a623023
Epcoritamab-bysp Injection | Cigna
Epcoritamab-bysp is used for treatment of diffuse large B-cell lymphoma (DLBCL; a type of cancer that impacts the lymphatic [infection-fighting] system in the...
epcoritamab byspinjectioncigna
https://www.medlineplus.gov/druginfo/meds/a623023.html
Epcoritamab-bysp Injection: MedlinePlus Drug Information
Epcoritamab-bysp Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus
epcoritamab byspinjectionmedlineplusdruginformation
https://medlineplus.gov/druginfo/meds/a623023.html
Epcoritamab-bysp Injection: MedlinePlus Drug Information
Epcoritamab-bysp Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus
epcoritamab byspinjectionmedlineplusdruginformation
https://www.cancer.gov/about-cancer/treatment/drugs/epcoritamab-bysp
Epcoritamab-bysp - NCI
Epcoritamab-bysp works by bringing healthy T cells (immune cells that help kill cancer cells) and lymphoma cells close together so the T cells can more...
epcoritamab byspnci
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-epcoritamab-bysp-relapsed-or-refractory-diffuse-large-b-cell
FDA grants accelerated approval to epcoritamab-bysp for relapsed or refractory diffuse large B-cell...
FDA grants accelerated approval to epcoritamab-bysp for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-epcoritamab-bysp-relapsed-or-refractory-follicular-lymphoma
FDA grants accelerated approval to epcoritamab-bysp for relapsed or refractory follicular lymphoma...
On June 26, 2024, the Food and Drug Administration granted accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.), a bispecific CD20-directed CD3...